Cognoa is a pediatric behavioral health company developing digital diagnostics and therapeutics to enable the earlier diagnosis and treatment of behavioral health conditions, such as autism. We are dedicated to improving lifelong outcomes for children at risk for developmental delay and their families. Our lead products, the first digital diagnosis aid for autism and the first prescription digital therapeutic for children diagnosed with autism, have both received Breakthrough Device designation from the FDA. The company’s AI technology platform will enable Cognoa's product pipeline to address additional unmet needs including ADHD and anxiety. Cognoa plans to commercialize its autism diagnosis aid under the name, Canvas Dx™. For additional information and to receive updates on availability for Canvas Dx™, please visit CanvasDx.com.